Q1 2026 · 13F-HR
Atlas Venture Life Science Advisors, LLCholdings as filed
Filed 2026-05-14 · accession 0001104659-26-061232
$790.0M
Reported value
6
Positions
2026-03-31
Period end
The Brief · Atlas Venture Life Science Advisors, LLC · Q1 2026
AI · grounded in 13F
Atlas Venture Life Science Advisors, LLC closed its position in Day One Biopharmaceuticals, Inc. DAWNGBX, reducing its holdings by $59.77M. The fund also exited its position in Generation Bio, Co., resulting in a $4.7M decrease. Additionally, the fund trimmed its stake in Kymera Therapeutics, Inc. KYMR by 1.76%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $381.3M | 48.3% | 4,578,008 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $165.5M | 21.0% | 9,130,465 | Common | SOLE |
| 829401108 | SION | Sionna Therapeutics, Inc. | $120.1M | 15.2% | 2,995,602 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $96.8M | 12.3% | 1,513,875 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio, Inc. | $13.4M | 1.70% | 2,092,106 | Common | SOLE |
| 500946108 | KRRO | Korro Bio, Inc. | $12.9M | 1.63% | 1,137,149 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.